CALA

In a report released yesterday, Nick Abbott from Wells Fargo maintained a Hold rating on Calithera Bio (CALA – Research Report), with a price target of $2.00. The company's shares closed last Wednesday at $0.16, close to its 52-week low of $0.16. According to TipRanks.com, Abbott is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -45.2% and a 6.3% success rate. Abbott covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Arcturus Therapeutics, and Alaunos Therapeutics. Calithera Bio has an analyst consensus of Moderate Buy, with a price target consensus of $1.83, a 773.9% upside from current levels.
https://www.tipranks.com/news/blurbs/calithera-bio-cala-gets-a-hold-rating-from-wells-fargo?utm_source=advfn.com&utm_medium=referral